Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney … (NCT04388761) | Clinical Trial Compass
WithdrawnPhase 1
Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)
Stopped: Challenges in recruiting participants.
0Started 2020-09
Plain-language summary
The purpose of this research is to test an investigational drug called Adipose Mesenchymal Stem Cells (aMSCs) for the treatment of ischemia re-perfusion injury (IRI) in patients that have had a kidney transplant.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female kidney transplant candidates age 18 and above.
* Patient is receiving kidney allograft from deceased donor with KDPI\>85%.
* Ability of subject to give appropriate consent.
* Females of childbearing potential with agreement to use birth control for six months post-transplant.
* Approved by the Mayo Clinic Transplant Selection Committee.
* Signed Authorization for Donation of Anatomical Gifts on file.
Exclusion Criteria:
* Positive pregnancy test at the time of the kidney offer is called for the potential recipient.
* Kidney transplant potential recipients with active malignancy (except none melanoma skin malignancies).
* Patients with previous history of solid organ transplant (Heart, Lung, Intestine, Kidney and/or Pancreas).
* Patients with previous history of bone marrow transplant.